COMMUNIQUÉS West-GlobeNewswire

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
02/07/2026
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and “CRGT” [...]
Cannara obtient les droits exclusifs au Canada sur la technologie d’infusion Ampersand™ Live Rosin de Blue River
02/07/2026
Ce partenariat associe le leadership de Cannara dans le domaine du cannabis haut de gamme sans solvant à la technologie d’infusion exclusive de Blue River afin de proposer une nouvelle génération de produits à base de [...]
Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand™ Live Rosin Infusion Technology
02/07/2026
Partnership combines Cannara's leadership in premium solventless cannabis with Blue River's proprietary infusion technology to bring a new generation of live rosin products to Canadian consumers MONTREAL, July 02, 2026 [...]
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and [...]
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer
02/07/2026
BASEL, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
02/07/2026
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across [...]
Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
02/07/2026
ESMO GI poster highlights increased intratumoral CD8+ T-cell infiltration, PD-L1 expression, expansion of tumor-reactive TCR clonotypes and association with clinical outcome LONDON and BOSTON and BUDAPEST, Hungary, July [...]
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
02/07/2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE [...]
The Ensign Group Purchases Real Estate and Operations in Texas
02/07/2026
SAN JUAN CAPISTRANO, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with [...]
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)
02/07/2026
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€) PARIS, France, 2 juillet 2026 – 08h00 CEST – [...]
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
02/07/2026
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free [...]
DXS INTERNATIONAL PLC (AQSE: DXSP): Trading Update
02/07/2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union ( [...]
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
02/07/2026
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (Euronext Paris: [...]
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
02/07/2026
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option [...]
FDA Alignment to Advance ProstACT Global Phase 3 Trial
02/07/2026
FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States. FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care [...]
GNI Group Completes Acquisition of AYUMI Pharmaceutical
02/07/2026
Japan-Originated Global Biopharma Company Founded in 2001 Enters Its “Second Founding Phase” TOKYO, July 01, 2026 (GLOBE NEWSWIRE) -- GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has [...]
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
02/07/2026
SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Pages